Loading...
XJPX4523
Market cap7.54bUSD
Dec 23, Last price  
4,273.00JPY
1D
-1.00%
1Q
-23.52%
Jan 2017
-36.30%
Name

Eisai Co Ltd

Chart & Performance

D1W1MN
XJPX:4523 chart
P/E
27.95
P/S
1.60
EPS
152.89
Div Yield, %
3.87%
Shrs. gr., 5y
—
Rev. gr., 5y
2.90%
Revenues
741.75b
-0.36%
533,139,000,000601,258,000,000674,175,000,000734,419,000,000781,708,000,000803,138,000,000768,925,000,000647,925,000,000573,676,000,000600,353,000,000548,465,000,000547,922,000,000539,097,000,000600,054,000,000642,834,000,000695,621,000,000645,942,000,000756,226,000,000744,402,000,000741,751,000,000
Net income
42.41b
-23.50%
55,505,000,00063,410,000,00070,614,000,000-17,012,000,00047,678,000,00040,338,000,00067,394,000,00058,511,000,00048,275,000,00032,955,000,00043,253,000,00054,934,000,00039,359,000,00051,845,000,00063,386,000,000121,767,000,00041,942,000,00047,954,000,00055,432,000,00042,407,000,000
CFO
55.99b
P
49,200,000,00087,053,000,00081,188,000,00073,242,000,000104,988,000,000107,947,000,000123,157,000,00090,624,000,00073,181,000,00085,687,000,00076,022,000,00095,617,000,00075,851,000,000149,649,000,000103,714,000,000102,782,000,00073,853,000,000117,590,000,000-1,772,000,00055,993,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Feb 04, 2025

Profile

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
URL
https://www.eisai.co.jp/
IPO date
Sep 14, 1961
Employees
11,076
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
741,751,000
-0.36%
744,402,000
-1.56%
756,226,000
17.07%
Cost of revenue
688,438,000
709,128,000
712,999,000
Unusual Expense (Income)
NOPBT
53,313,000
35,274,000
43,227,000
NOPBT Margin
7.19%
4.74%
5.72%
Operating Taxes
18,040,000
(11,824,000)
8,741,000
Tax Rate
33.84%
20.22%
NOPAT
35,273,000
47,098,000
34,486,000
Net income
42,407,000
-23.50%
55,432,000
15.59%
47,954,000
14.33%
Dividends
(45,915,000)
(45,893,000)
(45,878,000)
Dividend yield
2.58%
2.13%
2.82%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
34,240,000
41,201,000
9,947,000
Long-term debt
172,506,000
120,775,000
133,085,000
Deferred revenue
38,288,000
40,686,000
Other long-term liabilities
54,875,000
17,978,000
18,387,000
Net debt
(156,797,000)
(179,789,000)
(231,985,000)
Cash flow
Cash from operating activities
55,993,000
(1,772,000)
117,590,000
CAPEX
(14,321,000)
(34,559,000)
(40,467,000)
Cash from investing activities
(25,321,000)
(22,723,000)
(28,848,000)
Cash from financing activities
(22,720,000)
(24,522,000)
(48,967,000)
FCF
(22,766,000)
(19,022,000)
51,643,000
Balance
Cash
305,123,000
267,890,000
310,065,000
Long term investments
58,420,000
73,875,000
64,952,000
Excess cash
326,455,450
304,544,900
337,205,700
Stockholders' equity
853,724,000
1,390,331,000
1,323,102,000
Invested Capital
796,407,550
698,174,100
591,363,300
ROIC
4.72%
7.30%
5.83%
ROCE
4.74%
3.52%
4.65%
EV
Common stock shares outstanding
286,803
286,761
286,729
Price
6,216.00
-17.16%
7,504.00
32.35%
5,670.00
-23.57%
Market cap
1,782,767,448
-17.15%
2,151,854,544
32.36%
1,625,753,430
-23.57%
EV
1,649,331,448
2,607,611,544
2,011,717,430
EBITDA
92,711,000
75,255,000
81,625,000
EV/EBITDA
17.79
34.65
24.65
Interest
2,388,000
2,266,000
1,692,000
Interest/NOPBT
4.48%
6.42%
3.91%